The winners of the Boston Bootcamp 2026 have been announced! Congratulations to ExpressionEdits, Monument Therapeutics, Profionics, and Stick Therapeutics. These four standout companies impressed a panel of esteemed UK and US judges during the online presentation session on 24 February, where 16 companies each pitched their vision in a 5-minute slot.
With the competition now moving ever closer towards the Boston visit (27–30 April), the focus shifts to preparatory sessions with Bootcamp supporters and sponsors. These sessions are designed to help participants refine their key questions,…
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform
Cambridge, UK, 31 March 2026: Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP). The fundraise was led by Parkwalk, and joined by The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The investment will facilitate commercial…
Rebrand follows appointment of new leadership as company drives commercialization of INDUCE-seq® platform to address regulatory gaps in off-target reporting for gene editing programs
Cambridge, UK, 31 March 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today introduced new branding and comprehensive website as part of its strategic repositioning. At a time where the gene editing industry is facing increasing regulatory demands for genome-wide off-target data, the update has…
In this episode, host Sonjoy Brahma, VP of Clinical Operations at tranScrip, is joined by Joab Williamson of Faron Pharmaceuticals to explore the operational realities of working within small emerging biotech companies. They discuss the challenges of rare oncology development, how cash runway and clinical milestones shape strategy, and why flexibility, external expertise and careful planning are essential to balanced decision-making. Together, they share practical insights into managing risk, controlling costs and advancing clinical programmes with confidence in a resource-constrained…
Sandwich, UK — 25 March 2026: Discovery Park, Kent’s science and innovation hub, has launched the sixth edition of its Discovery Spark accelerator programme, welcoming 11 startups to its campus in Sandwich.
The business growth programme has already supported 50 companies and 76 founders, with alumni securing £5.5m in UKRI funding since launching in 2023. For Cohort 6.0, the startups were selected based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Spark is designed to provide opportunities for companies to grow a network of peers,…
Amsbio announce the RPMotion – a spinning organoid bioreactor that facilitates fast, easy and efficient organoid culture for drug discovery, disease modelling and regenerative medicine.
Until now organoid expansion has been an expensive and time-consuming static process, requiring large amounts of materials, skilled labour and time. Benefiting from a novel bioreactor design – the RPMotion – overcomes current limitations in organoid expansion / differentiation methodologies, helping laboratories improve efficiency and reduce reliance on manual processes.…
LONDON, UK, March 18, 2026 / Biotech Newswire / -- Touchlight, in collaboration with New England Biolabs (NEB®), announces the launch of the EnClose™ Cell-free dbDNA™ Synthesis Kit, a new benchtop solution enabling rapid enzymatic production of Touchlight’s proprietary doggybone DNA™ (dbDNA™). This linear, covalently closed, double-stranded DNA format offers researchers a fast, cell-free alternative to traditional plasmid DNA, supporting the growing demand for nucleic acid therapeutics.
Traditional plasmid manufacturing remains a critical bottleneck for advanced therapy developers, often…
• Cutting-edge platform technology leveraging advanced molecular dynamics to uncover protein metastates and reveal novel binding sites in difficult to target proteins.
• Combining RxPlorer™ with our in vitro capabilities, RxCelerate can deliver rapid hit identification and screening in 2 months.
Cambridge, UK and Cambridge, MA – 24/3/26 1pm GMT
RxCelerate, a leading international outsourced drug discovery and development provider, today announced the launch of RxPlorer™: a new technology for finding small molecule hits, particularly against challenging, previously undruggable targets.…
We are pleased to announce the winners of the One Nucleus Awards 2026! The awards took place on 29 March in London.The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders.
Many congratulations to the winners and finalists:
Best Therapeutic R&D Programme of the Year⭐Winner: Resolution Therapeutics⭐Finalists: Serenatis Bio, TRIMTECH Therapeutics
Best Use of Emerging Technology of the Year⭐Winner: Nuclera⭐Finalists: Ignota Labs, Constructive Bio
Best Industry and Not-for-Profit…
New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.
The Science, Innovation and Technology Committee’s report emphasises that the UK is “flying blind” when it comes to public and private R&D spending, with major R&D funders unable to properly measure and map levels of investment, their outputs, and regional…